StreetInsider.com News Articles

Form 4 Monte Rosa Therapeutics, For: Mar 04 Filed by: Dunn Edmund

Thu, 05 Mar 2026 17:24:00 -0500

si-local-file:///var/storage/secattach/20260305/26120440.html

Form 4 Monte Rosa Therapeutics, For: Mar 04 Filed by: Dunn Edmund

Thu, 05 Mar 2026 17:24:00 -0500

si-local-file:///var/storage/secattach/20260305/26120440.html

Form 4 Monte Rosa Therapeutics, For: Mar 02 Filed by: Warmuth Markus

Wed, 04 Mar 2026 16:50:00 -0500

si-local-file:///var/storage/secattach/20260304/26112234.html

Form 4 Monte Rosa Therapeutics, For: Mar 02 Filed by: Warmuth Markus

Wed, 04 Mar 2026 16:50:00 -0500

si-local-file:///var/storage/secattach/20260304/26112234.html

Form 144 Monte Rosa Therapeutics, Filed by: Dunn Edmund

Wed, 04 Mar 2026 16:45:00 -0500

si-local-file:///var/storage/secattach/20260304/26112152.html

Form 144 Monte Rosa Therapeutics, Filed by: Dunn Edmund

Wed, 04 Mar 2026 16:45:00 -0500

si-local-file:///var/storage/secattach/20260304/26112152.html

Form 4 Monte Rosa Therapeutics, For: Feb 27 Filed by: Dunn Edmund

Mon, 02 Mar 2026 17:03:00 -0500

si-local-file:///var/storage/secattach/20260302/26093550.html

Form 4 Monte Rosa Therapeutics, For: Feb 27 Filed by: Dunn Edmund

Mon, 02 Mar 2026 17:03:00 -0500

si-local-file:///var/storage/secattach/20260302/26093550.html

Form 144 Monte Rosa Therapeutics, Filed by: Warmuth Markus

Mon, 02 Mar 2026 16:25:00 -0500

si-local-file:///var/storage/secattach/20260302/26092618.html

Form 144 Monte Rosa Therapeutics, Filed by: Warmuth Markus

Mon, 02 Mar 2026 16:25:00 -0500

si-local-file:///var/storage/secattach/20260302/26092618.html

Form 144 Monte Rosa Therapeutics, Filed by: Dunn Edmund

Mon, 02 Mar 2026 16:16:00 -0500

si-local-file:///var/storage/secattach/20260302/26092334.html

Form 144 Monte Rosa Therapeutics, Filed by: Dunn Edmund

Mon, 02 Mar 2026 16:16:00 -0500

si-local-file:///var/storage/secattach/20260302/26092334.html

Form 144 Monte Rosa Therapeutics, Filed by: Dunn Edmund

Fri, 27 Feb 2026 16:29:00 -0500

si-local-file:///var/storage/secattach/20260227/26082337.html

Form 144 Monte Rosa Therapeutics, Filed by: Dunn Edmund

Fri, 27 Feb 2026 16:29:00 -0500

si-local-file:///var/storage/secattach/20260227/26082337.html

Form 4 Monte Rosa Therapeutics, For: Feb 23 Filed by: Janku Filip

Tue, 24 Feb 2026 16:05:00 -0500

si-local-file:///var/storage/secattach/20260224/26051406.html

Form 4 Monte Rosa Therapeutics, For: Feb 23 Filed by: Janku Filip

Tue, 24 Feb 2026 16:05:00 -0500

si-local-file:///var/storage/secattach/20260224/26051406.html

Monte Rosa shows positive results for prostate cancer drug combination

Tue, 24 Feb 2026 07:01:20 -0500

Monte Rosa Therapeutics Inc. (NASDAQ: GLUE) reported clinical data from a Phase 1/2 study of its experimental drug MRT-2359 combined with enzalutamide in patients with metastatic castration-resistant prostate cancer.

The study included 23 patients with advanced prostate cancer who had received multiple prior treatments. Among patients with androgen receptor mutations, all five showed PSA response rates, including two with PSA90 responses. The disease control rate reached 100% in this subset, with two partial responses and three cases of stable disease.

Across all 15 evaluable patients, the overall disease control rate was 67%, with 10 patients showing tumor size reductions. The combination was

Monte Rosa shows positive results for prostate cancer drug combination

Tue, 24 Feb 2026 07:01:20 -0500

Across all 15 evaluable patients, the overall disease control rate was 67%, with 10 patients showing tumor size reductions. The combination was

Monte Rosa Therapeutics Presents Updated Clinical Data from Phase 1/2 Study of MRT-2359 in Combination with Enzalutamide in Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer Patients

Tue, 24 Feb 2026 07:00:00 -0500

In mCRPC patients with androgen receptor (AR) mutations, treatment with MRT-2359 in combination with enzalutamide led to a 100% PSA response rate (5 of 5 patients) and a 100% disease control rate, including 2 patients with RECIST partial responses and 3 with stable disease, all showing reduction in size of target lesions

Across all 15 evaluable patients, the overall RECIST disease control rate was 67%, and 10 of 15 patients showed tumor size reductions of target lesions

Combination of MRT-2359 and enzalutamide was generally well-tolerated with primarily Grade 1-2 adverse events (AEs); no treatment discontinuations due

Monte Rosa Therapeutics Presents Updated Clinical Data from Phase 1/2 Study of MRT-2359 in Combination with Enzalutamide in Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer Patients

Tue, 24 Feb 2026 07:00:00 -0500

In mCRPC patients with androgen receptor (AR) mutations, treatment with MRT-2359 in combination with enzalutamide led to a 100% PSA response rate (5 of 5 patients) and a 100% disease control rate, including 2 patients with RECIST partial responses and 3 with stable disease, all showing reduction in size of target lesions

Across all 15 evaluable patients, the overall RECIST disease control rate was 67%, and 10 of 15 patients showed tumor size reductions of target lesions

Combination of MRT-2359 and enzalutamide was generally well-tolerated with primarily Grade 1-2 adverse events (AEs); no treatment discontinuations due

Monte Rosa Therapeutics Presents Updated Clinical Data from Phase 1/2 Study of MRT-2359 in Combination with Enzalutamide in Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer Patients

Tue, 24 Feb 2026 07:00:00 -0500

In mCRPC patients with androgen receptor (AR) mutations, treatment with MRT-2359 in combination with enzalutamide led to a 100% PSA response rate (5 of 5 patients) and a 100% disease control rate, including 2 patients with RECIST partial responses and 3 with stable disease, all showing reduction in size of target lesions

Across all 15 evaluable patients, the overall RECIST disease control rate was 67%, and 10 of 15 patients showed tumor size reductions of target lesions

Combination of MRT-2359 and enzalutamide was generally well-tolerated with primarily Grade 1-2 adverse events (AEs); no treatment discontinuations due

Monte Rosa Therapeutics Presents Updated Clinical Data from Phase 1/2 Study of MRT-2359 in Combination with Enzalutamide in Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer Patients

Tue, 24 Feb 2026 07:00:00 -0500

In mCRPC patients with androgen receptor (AR) mutations, treatment with MRT-2359 in combination with enzalutamide led to a 100% PSA response rate (5 of 5 patients) and a 100% disease control rate, including 2 patients with RECIST partial responses and 3 with stable disease, all showing reduction in size of target lesions

Across all 15 evaluable patients, the overall RECIST disease control rate was 67%, and 10 of 15 patients showed tumor size reductions of target lesions

Combination of MRT-2359 and enzalutamide was generally well-tolerated with primarily Grade 1-2 adverse events (AEs); no treatment discontinuations due

Form 144 Monte Rosa Therapeutics, Filed by: Janku Filip

Mon, 23 Feb 2026 17:42:00 -0500
si-local-file:///var/storage/secattach/20260223/26044815.html

Form 144 Monte Rosa Therapeutics, Filed by: Janku Filip

Mon, 23 Feb 2026 17:42:00 -0500
si-local-file:///var/storage/secattach/20260223/26044815.html

Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences

Mon, 23 Feb 2026 07:00:00 -0500

BOSTON, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that management will participate in the following investor conferences:

TD Cowen 46th Annual Health Care Conference (Boston, MA) – Markus Warmuth, M.D., Chief Executive Officer, to present, March 2, 2026, at 3:10 p.m. ET
Barclays 28th Annual Global Healthcare Conference (Miami, FL) – Filip Janku, M.D., Chief Medical Officer, to participate in a fireside chat, March 10, 2026, at 12:30 p.m. ET
2026 Jefferies Biotech on the Beach